Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Exclusion Criteria

• •1. Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins.
• •2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins.
• •3. Any prior treatment with anti-VEGF agents in the study eye.
• •4. Total lesion size \> 12 disc areas (30.5 mm\^2, including blood, scars and neovascularization) as assessed by FA in the study eye.
• •5. Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible CNV.)
• •6. Scar or fibrosis, making up \> 50% of total lesion in the study eye.
• •7. Scar, fibrosis, or atrophy involving the center of the fovea.
• •8. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
• •9. History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
• •10. Presence of other causes of CNV in the study eye.
• •11. History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina,other than AMD, in either eye.
• •12. Prior vitrectomy in the study eye.
• •13. History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
• •14. Any history of macular hole of stage 2 and above in the study eye.
• •15. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as its unlikely to interfere with the injection.